Corrigendum: Targeting Interleukin-17 and Th17 in Immune Inflammatory Diseases

Abstract

Th17 cells (Th17) are a distinct lineage of CD4+ T cells that secrete high amounts of IL-17 under orphan nuclear receptor retinoic acid receptor-related orphan receptor γt (RORγt) which is a lineage-specific transcription factor. TGF-β and inflammatory cytokines, such as IL-6, IL-21, IL-1β, and IL-23, play central roles in the generation of Th17 cells. Th17 cells and their effector molecules, such as IL-17A, IL-17F, IL-21, IL-22, and CCL20, contribute to the progression and pathogenesis of several autoimmune and inflammatory diseases, such as rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease and sys- temic lupus erythematosus. Studies of Th17 development and the effects of IL-17 signal- ing in autoimmune responses suggest a high potential for targeting this pathway in im- mune pathologies. In this review, we discuss Th17 biology in relation to autoinflammatory disorders and the various therapeutic strategies under investigation which target the IL- 17–Th17 cell pathway in chronic inflammatory autoimmune disorders. KeyWords: Th17Cells;Receptors,Interleukin-17;AutoimmuneDiseases;Therapeutics